Type2 Diabetes Mellitus Clinical Trial
Official title:
A 12-Week Double-Blind of Diabetes Nutrition Education in T2D
NCT number | NCT04440319 |
Other study ID # | Andalas U |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | July 1, 2020 |
Est. completion date | March 31, 2021 |
Verified date | February 2022 |
Source | Andalas University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
T2DM in Indonesia has increased dramatically from 7.0% in 2017 to 10.9% in 2018. In Padang, West Sumatra, diabetes prevalence was 1.3% in 2013 and increased slowly in 2018. Majority of T2DM were not able to achieve optimal glycaemic glucose control measured using HbA1c with a target of less than < 6.5% based on WHO recommendation. Problem Statement NCD guidelines provided management DM in general. Pedoman Gizi Seimbang was for healthy people. It is crucial to update the guideline following the current issues even the Indonesian consensus in 2015 provided a T2DM management diet. Study Hypotheses There is a significant difference in glycemic control (HbA1c and FBG) nutritional status, knowledge, attitude, practice, quality of life, acceptability and adherence behavior among individuals with T2DM in intervention group. Procedures Subjects will be divided into Intervention and control groups after they finished reading, signed a letter of agreement and informed consent. Subjects also have the right to be withdrawn after listening explanation of the investigators to seeking the potential participants based on inclusion criteria. The individual with T2DM (intervention group) will follow the Diabetes Mellitus Nutrition Education (DNE) program based on the curriculum of DNE modules properly and certain measurements. There is a selected nutritionist at each PHC who will convey the DNE program. DM nutrition education counseling will be delivered every week for 30 minutes. Individual with T2DM - Baseline An individual with T2DM will be asked to fill the questionnaire and follow all of the measurements (Nutritional Status, Biochemical, Clinical, and Dietary Intake). - Intervention (3 months) All of the subjects will follow the DM Nutrition Education program for 3 months which will be delivered by nutritionists in PHC. - Follow up (3 months) All of the subjects will continue the program independently in 3 months. Then, the subjects will do the same activity as a baseline to compare the data between baselines, intervention and follow up Control The individual with T2DM in the control group will still follow the conventional DM nutrition education. After the DNE program finished, the material will also be distributed to the individual with T2DM in the control group.
Status | Completed |
Enrollment | 150 |
Est. completion date | March 31, 2021 |
Est. primary completion date | January 30, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: - T2DM Patients with new diagnosed at least 6 months - Patients with range age 18-65 years old - Male and female who can read and write - Patients can communicate well Exclusion Criteria: - T2DM patients with stroke and complication - T2DM patients who are pregnant and breastfeeding women |
Country | Name | City | State |
---|---|---|---|
Indonesia | Ice Yolanda Puri | Padang | WEST Sumatera |
Lead Sponsor | Collaborator |
---|---|
Andalas University | Universiti Putra Malaysia |
Indonesia,
Barakatun Nisak MY, Ruzita AT, Norimah AK, Kamaruddin NA. Medical nutrition therapy administered by a dietitian yields favourable diabetes outcomes in individual with type 2 diabetes mellitus. Med J Malaysia. 2013;68(1):18-23. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | HbA1c and Fasting blood glucose | HbA1c will be analyzed using high performance liquid chromatography, D-10. 158 subjects will be asked to fasting before fasting blood glucose measurement, which will be undertaken by trained clinical staff. | 3 months | |
Primary | Statistical analyses for HbA1c and Fasting blood glucose | Statistical analyses will be performed using the latest version of STATA. The data will be checked for normality. Descriptive statistics will be expressed as portions, mean (SD). The time trend for the treatment effect will be estimated from the General Linear Model (GLM). GLM is to determine the between-group difference at 3 months intervention. Differences between baseline, treatment 3 (three) months will be calculated for each outcome. Estimation within and between intervention and control groups will be tested using two way-ANOVA. Sociodemographic characteristic data will be expressed as proportions, mean and Standard Deviation (SD). One-way repeated measured ANOVA is to test the independent variable and a continuous (interval or ratio) dependent variable (within groups). Then, two-way repeated measured ANOVA to test the independent variable and dependent variable between groups. | 3 months | |
Secondary | Blood Pressure | Blood pressure (mm Hg) will be measured following Indonesian consensus 2015. They divides into Systolic < 140mmHg and Diastolic <90mmHg. | 3 months | |
Secondary | Statistical analyses for Blood Pressure | Statistical analyses will be performed using the latest version of STATA. The data will be checked for normality. Descriptive statistics will be expressed as portions, mean (SD). The time trend for the treatment effect will be estimated from the General Linear Model (GLM). GLM is to determine the between-group difference at 3 months intervention. Differences between baseline, treatment 3 (three) months will be calculated for each outcome. Estimation within and between intervention and control groups will be tested using two way-ANOVA. Sociodemographic characteristic data will be expressed as proportions, mean and Standard Deviation (SD). One-way repeated measured ANOVA is to test the independent variable and a continuous (interval or ratio) dependent variable (within groups). Then, two-way repeated measured ANOVA to test the independent variable and dependent variable between groups | 3 months | |
Secondary | Body Mass Index (BMI), assessed by Seca-Tanita scale | BMI (kg/m2) will be measured by Seca - Tanita scale. Indonesian consensus 2015 divides Body Mass Index (BMI) for T2DM become : BMI underweight (<18.5);BMI normal (from 18.5 to 22.9);BMI overweight (=23.0);BMI with the risk of overweight (23.0- 24.9);Obesity I (25.0 - 29.9);Obesity II (=30). | 3 months | |
Secondary | Statistical analyses for Body Mass Index (BMI) | Statistical analyses will be performed using the latest version of STATA. The data will be checked for normality. Descriptive statistics will be expressed as portions, mean (SD). The time trend for the treatment effect will be estimated from the General Linear Model (GLM). GLM is to determine the between-group difference at 3 months intervention. Differences between baseline, treatment 3 (three) months will be calculated for each outcome. Estimation within and between intervention and control groups will be tested using two way-ANOVA. Sociodemographic characteristic data will be expressed as proportions, mean and Standard Deviation (SD). One-way repeated measured ANOVA is to test the independent variable and a continuous (interval or ratio) dependent variable (within groups). Then, two-way repeated measured ANOVA to test the independent variable and dependent variable between groups. | 3 months | |
Secondary | Knowledge-Attitude-Practice DM questionnaire | Knowledge-Attitude-Practice DM questionnaires are adapted from Besher Gharaibeh, Fatema et al and Indonesian Ministry of Health questionnaire. There are 17 knowledge questionnaires, 25 attitude questionnaires, and 7 practices questionnaires.
Knowledge The knowledge categorical will be divided into high, moderate, and low level. The high score is 14-17, the moderate score is 7-13, and the lowest score is 0-6. Attitude The highest score is 43-125, the moderate score is 26-42, and the lowest score is 0-25 1 = Do not extremely agree 2= Do not agree 3 = Not sure 4 = Agree 5 = extremely agree Practice The practice categorical will be divided into high, moderate, and low level. The high score is 6-7, the moderate score is 3-5, and the lowest score is 0-6. |
3 months | |
Secondary | Statistical analyses for knowledge-attitude-practice DM | Statistical analyses will be performed using the latest version of STATA. The data will be checked for normality. Descriptive statistics will be expressed as portions, mean (SD). The time trend for the treatment effect will be estimated from the General Linear Model (GLM). GLM is to determine the between-group difference at 3 months intervention. Differences between baseline, treatment 3 (three) months will be calculated for each outcome. Estimation within and between intervention and control groups will be tested using two way-ANOVA. Sociodemographic characteristic data will be expressed as proportions, mean and Standard Deviation (SD). One-way repeated measured ANOVA is to test the independent variable and a continuous (interval or ratio) dependent variable (within groups). Then, two-way repeated measured ANOVA to test the independent variable and dependent variable between groups. | 3 months | |
Secondary | Quality of life, assessed by DM Quality of Life questionnaire | There are 16 quality of life DM question, is adapted from Singh as previous studies, and following Likert scale.
The highest score is 28-80, the moderate score is 17-27, and the lowest score is 0- 16 1 = not extremely satisfied 2= not agree satisfied 3 = Not sure 4 = satisfied 5 = extremely satisfied |
3 months | |
Secondary | Statistical analyses for quality of life | Statistical analyses will be performed using the latest version of STATA. The data will be checked for normality. Descriptive statistics will be expressed as portions, mean (SD). The time trend for the treatment effect will be estimated from the General Linear Model (GLM). GLM is to determine the between-group difference at 3 months intervention. Differences between baseline, treatment 3 (three) months will be calculated for each outcome. Estimation within and between intervention and control groups will be tested using two way-ANOVA. Sociodemographic characteristic data will be expressed as proportions, mean and Standard Deviation (SD). One-way repeated measured ANOVA is to test the independent variable and a continuous (interval or ratio) dependent variable (within groups). Then, two-way repeated measured ANOVA to test the independent variable and dependent variable between groups. | 3 months | |
Secondary | Waist Circumference (WC) | Waist Circumference (WC) is predictor parameter of T2DM. WC for man is =94 cm and for woman is Woman = 80 cm. | 3 months | |
Secondary | Statistical analyses for Waist Circumference | Statistical analyses will be performed using the latest version of STATA. The data will be checked for normality. Descriptive statistics will be expressed as portions, mean (SD). The time trend for the treatment effect will be estimated from the General Linear Model (GLM). GLM is to determine the between-group difference at 3 months intervention. Differences between baseline, treatment 3 (three) months will be calculated for each outcome. Estimation within and between intervention and control groups will be tested using two way-ANOVA. Sociodemographic characteristic data will be expressed as proportions, mean and Standard Deviation (SD). One-way repeated measured ANOVA is to test the independent variable and a continuous (interval or ratio) dependent variable (within groups). Then, two-way repeated measured ANOVA to test the independent variable and dependent variable between groups. | 3 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT04082091 -
Screening, Early Referral and Lifestyle Tailored E_prescription for Cardiovascular Prevention
|
||
Active, not recruiting |
NCT02248311 -
"Preventing Cardiovascular Ischemic Events and Arresting Their Consequences in Type 2 Diabetic Population
|
N/A | |
Completed |
NCT02653300 -
A Pilot Study to Assess the Safety of Oral Insulin in Patients With Nonalcolholic Steatohepatitis (NASH)
|
Phase 2 | |
Completed |
NCT03655535 -
Multicenter Study to Evaluate the Effect of BTI320 on Glycemic Control in Type 2 Diabetes
|
Phase 2 | |
Completed |
NCT03256747 -
Effects of Neuromuscular Electrical Stimulation on Glucose Variability in Patients With Type 2 Diabetes
|
N/A | |
Completed |
NCT05343767 -
Investigate the Efficacy and Safety of Low-Glu in Patients Newly Diagnosed With Type II Diabetes Mellitus
|
N/A | |
Withdrawn |
NCT03675074 -
Neujia Anastomosis for Treatment of Obesity and Type II Diabetes
|
N/A | |
Withdrawn |
NCT03190798 -
Effects of Canagliflozin on Intravascular Volume and Hemodynamics
|
Phase 4 | |
Withdrawn |
NCT03437330 -
Empagliflozin Effect on Glucose Toxicity
|
Phase 4 | |
Withdrawn |
NCT03008395 -
Empowerment, Motivation and Medical Adherence (EMMA).
|
N/A | |
Not yet recruiting |
NCT05539066 -
AI Health Assistant and Type 2 Diabetes
|
N/A | |
Completed |
NCT03682445 -
Metabolic, Physical Responses To Exercise In Patients With Type 2 Diabetes Mellitus
|
N/A | |
Not yet recruiting |
NCT03239119 -
The Effectivity and Safety Study of rExenatide-4 in Chinese Type 2 Diabetes Mellitus
|
Phase 3 | |
Completed |
NCT03259789 -
Safety and Efficacy of Bexagliflozin Compared to Placebo as Add-on Therapy to Metformin in Type 2 Diabetes Subjects
|
Phase 3 | |
Recruiting |
NCT03506230 -
Financial Incentives for Low Socioeconomic Diabetic Patients
|
N/A | |
Completed |
NCT03072407 -
MAD Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PB-119 to Subjects With T2DM
|
Phase 1 | |
Completed |
NCT05668442 -
Feasibility of an Online Exercise Community Among Individuals With Type 2 Diabetes
|
||
Completed |
NCT02964572 -
Effect of Sodium Glucose Co-transporter 2 Inhibitor on Inflammatory Cytokine in Type 2 Diabetes
|
N/A | |
Completed |
NCT02956044 -
Interaction of Bexagliflozin With Metformin, Glimepiride and Sitagliptin
|
Phase 1 | |
Completed |
NCT02628392 -
A Phase 2 Study of DS-8500a in Japanese Subjects With Type 2 Diabetes Mellitus (T2DM)
|
N/A |